Jun 22 2026 eGenesis Appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer Company
Jun 18 2026 eGenesis to Participate at BIO International Convention 2026 Panel on the Future of Xenotransplantation Company
Mar 24 2026 eGenesis Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 Company
Aug 19 2025 eGenesis Appoints Douglas Williams , Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors Company
Sep 04 2024 eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant Company
Feb 13 2024 eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan Kidney Company
Oct 25 2023 eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference Company
Oct 10 2023 eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys Company
Jun 13 2023 eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant Company